Oramed Pharmaceuticals Inc (ORMP) - Total Liabilities
Based on the latest financial reports, Oramed Pharmaceuticals Inc (ORMP) has total liabilities worth $30.57 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Oramed Pharmaceuticals Inc - Total Liabilities Trend (2003–2025)
This chart illustrates how Oramed Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital to net assets of Oramed Pharmaceuticals Inc to evaluate short-term liquidity relative to the company's equity base.
Oramed Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Oramed Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Wanhwa Enterprise Co
TW:2701
|
Taiwan | NT$1.39 Billion |
|
Marti Technologies Inc.
NYSE:MRT
|
USA | $90.38 Million |
|
BankFinancial Corporation
NASDAQ:BFIN
|
USA | $1.30 Billion |
|
THETA GOLD MNS LTD
F:3LM
|
Germany | €25.92 Million |
|
Den Networks Limited
NSE:DEN
|
India | Rs4.57 Billion |
|
Elentec Co. Ltd
KQ:054210
|
Korea | ₩366.85 Billion |
|
TGE Value Creative Solutions Corp
NYSE:BEBE
|
USA | $563.84K |
|
Torrid Holdings Inc
NYSE:CURV
|
USA | $613.75 Million |
Liability Composition Analysis (2003–2025)
This chart breaks down Oramed Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Oramed Pharmaceuticals Inc (ORMP) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.45 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Oramed Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Oramed Pharmaceuticals Inc (2003–2025)
The table below shows the annual total liabilities of Oramed Pharmaceuticals Inc from 2003 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $31.12 Million | +213.36% |
| 2024-12-31 | $9.93 Million | -82.78% |
| 2023-12-31 | $57.66 Million | +449.86% |
| 2022-12-31 | $10.49 Million | -8.67% |
| 2021-12-31 | $11.48 Million | -2.31% |
| 2020-12-31 | $11.75 Million | -23.03% |
| 2019-12-31 | $15.27 Million | -6.23% |
| 2018-12-31 | $16.29 Million | -16.38% |
| 2017-12-31 | $19.47 Million | +17.03% |
| 2016-12-31 | $16.64 Million | +990.43% |
| 2015-12-31 | $1.53 Million | +51.24% |
| 2014-12-31 | $1.01 Million | +90.59% |
| 2013-12-31 | $529.41K | -65.10% |
| 2012-12-31 | $1.52 Million | +151.96% |
| 2011-12-31 | $602.02K | -3.00% |
| 2010-12-31 | $620.62K | +20.35% |
| 2009-12-31 | $515.66K | -43.58% |
| 2008-12-31 | $913.95K | -35.82% |
| 2007-12-31 | $1.42 Million | +133.86% |
| 2006-12-31 | $608.91K | +1221.76% |
| 2005-12-31 | $46.07K | +360.68% |
| 2003-12-31 | $10.00K | -- |
About Oramed Pharmaceuticals Inc
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for C… Read more